Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

571 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP).
Banach M, Penson PE, Farnier M, Fras Z, Latkovskis G, Laufs U, Paneni F, Parini P, Pirro M, Reiner Ž, Vrablik M, Escobar C. Banach M, et al. Among authors: laufs u. Prog Cardiovasc Dis. 2023 Jul-Aug;79:2-11. doi: 10.1016/j.pcad.2023.03.001. Epub 2023 Mar 7. Prog Cardiovasc Dis. 2023. PMID: 36889490 Free article. Review.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Nissen SE, et al. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials.
Stroes ESG, Bays HE, Banach M, Catapano AL, Duell PB, Laufs U, Mancini GBJ, Ray KK, Sasiela WJ, Zhang Y, Gotto AM Jr. Stroes ESG, et al. Among authors: laufs u. Atherosclerosis. 2023 May;373:1-9. doi: 10.1016/j.atherosclerosis.2023.03.020. Epub 2023 Apr 3. Atherosclerosis. 2023. PMID: 37075696 Free article.
PCSK9-directed therapies: an update.
Katzmann JL, Laufs U. Katzmann JL, et al. Among authors: laufs u. Curr Opin Lipidol. 2024 Jun 1;35(3):117-125. doi: 10.1097/MOL.0000000000000919. Epub 2024 Jan 19. Curr Opin Lipidol. 2024. PMID: 38277255 Review.
Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe - Methodology and rationale for the multinational observational SANTORINI study.
Ray KK, Haq I, Bilitou A, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, Hildebrandt P, Laufs U, Mostaza JM, Nanchen D, Rietzschel E, Strandberg T, Toplak H, Visseren FLJ, Catapano AL. Ray KK, et al. Among authors: laufs u. Atheroscler Plus. 2021 Aug 13;43:24-30. doi: 10.1016/j.athplu.2021.08.003. eCollection 2021 Sep. Atheroscler Plus. 2021. PMID: 36644508 Free PMC article.
571 results